| Status: | Phase 2 |
| Entry Type: | Small molecule |
| Molecule Category: | UNKNOWN |
| UNII: | Y66IS3CS0R |
Physicochemical Descriptors
| Property Name | Value |
|---|---|
| Molecular Formula | C17H14N6 |
| Molecular Weight | 302.34 |
| AlogP | 3.35 |
| Hydrogen Bond Acceptor | 5.0 |
| Hydrogen Bond Donor | 3.0 |
| Number of Rotational Bond | 3.0 |
| Polar Surface Area | 92.51 |
| Molecular species | None |
| Aromatic Rings | 4.0 |
| Heavy Atoms | 23.0 |
Pharmacology
| Action | Mechanism of Action | Reference |
|---|---|---|
| INHIBITOR | Tyrosine-protein kinase receptor FLT3 inhibitor |
| Primary Target | |
|---|---|
| fms related receptor tyrosine kinase 3 | |
| KIT proto-oncogene, receptor tyrosine kinase |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Enzyme
Kinase
Protein Kinase
TK protein kinase group
Tyrosine protein kinase FGFR family
|
- | 120 | - | - | - | |
|
Enzyme
Kinase
Protein Kinase
TK protein kinase group
Tyrosine protein kinase PDGFR family
|
- | 6 | - | - | - |
Indications
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Leukemia, Myeloid, Acute | 1 | D015470 | ClinicalTrials |
Cross References
| Resources | Reference |
|---|---|
| CAS NUMBER | 1175017-90-9 |
| ChEMBL | CHEMBL3545281 |
| FDA SRS | Y66IS3CS0R |
| Guide to Pharmacology | 7969 |
| PubChem | 44177328 |
CONTENTS